XML 76 R65.htm IDEA: XBRL DOCUMENT
v3.25.2

In-licensing and Other Research and Development Agreements - Additional Information (Details) - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended | 6 Months Ended |
--- | --- | --- | --- | ---
Sep. 30, 2023 | Jun. 30, 2025 | Jun. 30, 2024 | Jun. 30, 2025 | Jun. 30, 2024 | Aug. 31, 2016
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Total segment research and development |  | $ 111,231 | $ 114,695 | $ 222,662 | $ 255,667 |
Children intended for treatment with Canavan Disease, under the age | 5 years |  |  |  |  |
BridgeBio Gene Therapy, LLC |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Maximum required future payment upon achievement of certain development and milestone events net sales metrics | $ 10,000 |  |  |  |  |
Adrenas |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Maximum required future payment upon achievement of certain development and milestone events net sales metrics | $ 10,000 |  |  |  |  |
Resilience DMSAs |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Agreement term | 10 years |  |  |  |  |
Agreement additional extension period | 2 years |  |  |  |  |
Resilience PAs | BridgeBio Gene Therapy, LLC |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Cost sharing credit of the lesser of a fixed percentage of certain agreed upon service costs | $ 15,500 |  |  |  |  |
Resilience PAs | Adrenas |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Cost sharing credit of the lesser of a fixed percentage of certain agreed upon service costs | $ 29,300 |  |  |  |  |
Resilience Agreements |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Total segment research and development |  |  | 400 | 1,200 | 900 |
Cost sharing credits received |  |  | $ 500 |  | 1,100 |
Eidos Therapeutics, Inc | Stanford License Agreement |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
License fees |  | 2,400 |  | 6,900 | $ 8,100 |
Royalties on net product revenue |  | $ 1,100 |  | $ 1,700 |  |
Milestone payments |  |  |  |  |  | $ 1,000

X
- Definition Agreement additional extension period option. + References No definition available. + Details
Name: | bbio_AgreementAdditionalExtensionPeriodOption
Namespace Prefix: | bbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Children intended for treatment with canavan disease maximum age. + References No definition available. + Details
Name: | bbio_ChildrenIntendedForTreatmentWithCanavanDiseaseMaximumAge
Namespace Prefix: | bbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cost sharing credit of the lesser of fixed percentage of certain agreed upon service costs. + References No definition available. + Details
Name: | bbio_CostSharingCreditOfTheLesserOfFixedPercentageOfCertainAgreedUponServiceCosts
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Cost sharing credits received. + References No definition available. + Details
Name: | bbio_CostSharingCreditsReceived
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License fees. + References No definition available. + Details
Name: | bbio_LicenseFees
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Maximum required future payment upon achievement of certain development and milestone events net sales metrics. + References No definition available. + Details
Name: | bbio_MaximumRequiredFuturePaymentUponAchievementOfCertainDevelopmentAndMilestoneEventsNetSalesMetrics
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Potential milestone payments. + References No definition available. + Details
Name: | bbio_PotentialMilestonePayments
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Service agreement term. + References No definition available. + Details
Name: | bbio_ServiceAgreementTerm
Namespace Prefix: | bbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_RoyaltyExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=bbio_BridgeBioGeneTherapyLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bbio_AdrenasTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bbio_DevelopmentAndManufacturingServicesAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bbio_ProjectAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bbio_ResilienceAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=bbio_EidosTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bbio_StanfordLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |